It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
SARS-CoV-2 variants and seasonal coronaviruses continue to cause disease and coronaviruses in the animal reservoir pose a constant spillover threat. Importantly, understanding of how previous infection may influence future exposures, especially in the context of seasonal coronaviruses and SARS-CoV-2 variants, is still limited. Here we adopted a step-wise experimental approach to examine the primary immune response and subsequent immune recall toward antigenically distinct coronaviruses using male Syrian hamsters. Hamsters were initially inoculated with seasonal coronaviruses (HCoV-NL63, HCoV-229E, or HCoV-OC43), or SARS-CoV-2 pango B lineage virus, then challenged with SARS-CoV-2 pango B lineage virus, or SARS-CoV-2 variants Beta or Omicron. Although infection with seasonal coronaviruses offered little protection against SARS-CoV-2 challenge, HCoV-NL63-infected animals had an increase of the previously elicited HCoV-NL63-specific neutralizing antibodies during challenge with SARS-CoV-2. On the other hand, primary infection with HCoV-OC43 induced distinct T cell gene signatures. Gene expression profiling indicated interferon responses and germinal center reactions to be induced during more similar primary infection-challenge combinations while signatures of increased inflammation as well as suppression of the antiviral response were observed following antigenically distant viral challenges. This work characterizes and analyzes seasonal coronaviruses effect on SARS-CoV-2 secondary infection and the findings are important for pan-coronavirus vaccine design.
Here, the authors analysed immune response to two consecutive coronavirus infections and observed that hamsters infected with seasonal coronaviruses were not protected from COVID-19 despite cross-reactive antibodies. Antiviral and germinal center B cell responses were suppressed but not during SARS-CoV-2 variant infections.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 University of Saskatchewan, Vaccine and Infectious Disease Organization VIDO, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Department of Biochemistry, Microbiology, and Immunology, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
2 University of Saskatchewan, Vaccine and Infectious Disease Organization VIDO, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
3 University of Saskatchewan, Department of Biochemistry, Microbiology, and Immunology, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
4 BC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service, Vancouver, Canada (GRID:grid.418246.d) (ISNI:0000 0001 0352 641X); University of British Columbia, School of Population and Public Health, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
5 Queen’s University, Department of Psychiatry, Kingston, Canada (GRID:grid.410356.5) (ISNI:0000 0004 1936 8331); Queen’s Genomics Lab at Ongwanada (Q-GLO), Ongwanada Resource Centre, Kingston, Canada (GRID:grid.410356.5)